EMA Authorised: Rolufta Ellipta (previously Rolufta) (umeclidinium bromide) — GlaxoSmithKline Trading Services Limited

View source ↗

Summary

The EMA authorised Rolufta Ellipta (umeclidinium bromide) for chronic obstructive pulmonary disease. The marketing authorization holder is GlaxoSmithKline Tradi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Rolufta Ellipta (umeclidinium bromide)

Snippet

Status: Authorised. Therapeutic area: Pulmonary Disease, Chronic Obstructive. MAH: GlaxoSmithKline Trading Services Limited. Decision date: 14/11/2024